Contact Us

Clinical Research Studies in Hoag Neurosciences Institute

Participation in research and clinical investigation is an important commitment of Hoag Neurosciences Institute in its mission to provide patients access to leading-edge management and treatment for neurological disorders.

Hoag’s sub-specialized team of neuroscientists are actively involved in research to discover new therapies, drugs and other medical advancements to better the lives of patients suffering from neurological conditions. Hoag Neurosciences Institute is currently accepting patients to participate in a number of clinical research trials.

Please contact Laura Whitaker, RN (949-764-8190 or [email protected]) or Channy Mai (949-764-8191 or [email protected]) to learn more about each protocol and whether you may qualify. Your participation in any trial is entirely voluntary. You may decide to withdraw at any time without losing the benefits of your standard medical care.

Clinical Research Studies for Brain Tumors

DC-Vax®-L for Glioblastoma (GBM)
Principal Investigator: Christopher Duma, MD, FACS

This randomized Phase III trial research trial is designed to evaluate the safety, clinical response and survival of patients following treatment with DCVax®-L, an immunotherapy treatment for patients with newly-diagnosed Glioblastoma Multiforme (also know as Glioblastoma, GBM and Grade IV Astrocytoma). This experimental therapy uses a patient's own tumor and white blood cells to create a patient-specific vaccine intended to "teach" the immune system how to recognize brain cancer cells.

Key to this study is that patients must begin study screening at Hoag Hospital Newport Beach before surgery to remove the tumor. DCVax®-L cannot be prepared from preserved tumor tissue. Study patients will receive standard of care treatment for GBM, including radiation and Temodar therapy, and two out of three will additionally receive DCVax®-L, with the remaining one-third receiving a placebo. Patients randomized to receive placebo will have the option to receive DCVax®-L in a crossover arm upon documented disease progression. (Note: DCVax®-L when used for patients with brain cancer is sometimes also referred to as DCVax®-Brain.)

Please contact Robin Ellis, RN, at 949-764-5543 or [email protected] to learn more. Additional information is also available at‚Äč.

Clinical Research Studies for Stroke

Clinical Research Studies for Alzheimer’s Disease